Literature DB >> 33347845

Nighttime Agitation in Persons with Dementia as a Manifestation of Restless Legs Syndrome.

Kathy C Richards1, Richard P Allen2, Janet Morrison3, Liam Fry4, Christine R Kovach5, Angelica Rangel3, Ana Loera3, Yanyan Wang3, Alexandra L Hanlon6, Alicia J Lozano6, Donald L Bliwise7.   

Abstract

OBJECTIVES: Nighttime agitation or "sundowning" is challenging for clinicians and caregivers to manage in older adults in the dementia stage of Alzheimer's disease (AD-D). Our research previously revealed that nighttime agitation might be a manifestation of restless legs syndrome (RLS). The current study aims to describe the characteristics of older adults with AD-D, nighttime agitation, and RLS, and to evaluate sleep disturbance and iron status in relation to nighttime agitation severity.
DESIGN: An observational study with baseline descriptive and correlational data from a clinical trial. SETTING AND PARTICIPANTS: Long-term care (n = 69) and independent living (n = 7); age 82.91 ± 9.46 years, with AD-D, nighttime agitation, and RLS. MEASUREMENTS: Trained observers counted nighttime agitation behaviors. Independent variables were age; cognition measured by the Mini-Mental State Examination; minutes slept from actigraphy; transferrin saturation percentage (TS%) and transferrin from fasting blood samples; and illness severity using the Cumulative Illness Rating Scale for Geriatrics. Bivariate and multivariable linear regression models were generated.
RESULTS: In the multivariable model, sleep minutes (P = .002) and TS% (P = .003) were negatively associated with frequency of nighttime agitation behaviors, and they explained 20% of the variance. Seventy-nine percent received 1 or more medications that worsen RLS symptoms, such as antihistamines and serotonin reuptake inhibitors. CONCLUSIONS AND IMPLICATIONS: We encourage clinicians to consider nighttime agitation as a manifestation of RLS. Treatment of iron deficiency indicated by low TS% and deprescribing medications that exacerbate RLS may decrease nighttime agitation, improve sleep, and enhance quality of life in older adults with AD-D.
Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Behavioral Indicators Test–Restless Legs; RLS; agitation; sleep disorders

Mesh:

Year:  2020        PMID: 33347845      PMCID: PMC8211902          DOI: 10.1016/j.jamda.2020.11.026

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   7.802


  21 in total

1.  Restless legs syndrome prevalence and impact: REST general population study.

Authors:  Richard P Allen; Arthur S Walters; Jacques Montplaisir; Wayne Hening; Andrew Myers; Timothy J Bell; Luigi Ferini-Strambi
Journal:  Arch Intern Med       Date:  2005-06-13

2.  Neuropsychiatric symptoms in Alzheimer's disease.

Authors:  Constantine G Lyketsos; Maria C Carrillo; J Michael Ryan; Ara S Khachaturian; Paula Trzepacz; Joan Amatniek; Jesse Cedarbaum; Robert Brashear; David S Miller
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

3.  Racial differences in restless legs symptoms and serum ferritin in an incident dialysis patient cohort.

Authors:  Nancy G Kutner; Rebecca Zhang; Yijian Huang; Donald L Bliwise
Journal:  Int Urol Nephrol       Date:  2012-01-05       Impact factor: 2.370

Review 4.  The role of actigraphy in the evaluation of sleep disorders.

Authors:  A Sadeh; P J Hauri; D F Kripke; P Lavie
Journal:  Sleep       Date:  1995-05       Impact factor: 5.849

5.  Validation of the Cumulative Illness Rating Scale in a geriatric residential population.

Authors:  P A Parmelee; P D Thuras; I R Katz; M P Lawton
Journal:  J Am Geriatr Soc       Date:  1995-02       Impact factor: 5.562

6.  Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.

Authors:  J C Morris
Journal:  Int Psychogeriatr       Date:  1997       Impact factor: 3.878

7.  Diagnostic accuracy of behavioral, activity, ferritin, and clinical indicators of restless legs syndrome.

Authors:  Kathy C Richards; James E Bost; Valerie E Rogers; Lisa C Hutchison; Cornelia K Beck; Donald L Bliwise; Christine R Kovach; Norma Cuellar; Richard P Allen
Journal:  Sleep       Date:  2015-03-01       Impact factor: 5.849

8.  Nighttime Agitation and Restless Legs Syndrome in Persons With Alzheimer's Disease: Study Protocol for a Double-Blind, Placebo-Controlled, Randomized Trial (NightRest).

Authors:  Kathy Richards; Janet Morrison; Yan-Yan Wang; Angelica Rangel; Ana Loera; Alexandra Hanlon; Alicia Lozano; Christine Kovach; Nalaka Gooneratne; Liam Fry; Richard Allen
Journal:  Res Gerontol Nurs       Date:  2020-09-24       Impact factor: 1.643

9.  The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia.

Authors:  Richard P Allen; Sarah Auerbach; Huzefa Bahrain; Michael Auerbach; Christopher J Earley
Journal:  Am J Hematol       Date:  2013-03-12       Impact factor: 10.047

10.  Restless legs syndrome risk factors, behaviors, and diagnoses in persons with early to moderate dementia and sleep disturbance.

Authors:  Kathy Richards; Valorie M Shue; Cornelia K Beck; Corinne W Lambert; Donald L Bliwise
Journal:  Behav Sleep Med       Date:  2010       Impact factor: 2.964

View more
  2 in total

Review 1.  Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Authors:  Kenneth M Heilman; Stephen E Nadeau
Journal:  Neurotherapeutics       Date:  2022-01-10       Impact factor: 6.088

Review 2.  Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer's Disease.

Authors:  Joshua P Roland; Donald L Bliwise
Journal:  Drugs Aging       Date:  2021-09-27       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.